drugmaker Archives - CFO

Gilead to Buy Cancer Drugmaker for $21 Billion

Gilead to Buy Cancer Drugmaker for $21 Billion

The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."

By Matthew Heller | September 14, 2020

J&J Speeds Up Timeline for Coronavirus Vaccine

Risk & Compliance

J&J Speeds Up Timeline for Coronavirus Vaccine

After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.

By Matthew Heller | July 16, 2020

Akorn Files for Chapter 11 After Failed Takeover

Credit & Capital

Akorn Files for Chapter 11 After Failed Takeover

The generic drugmaker listed $10 billion of debt and $10 billion of assets.

By Lauren Muskett | May 21, 2020

Gilead to Invest $5B in Galapagos Partnership

Gilead to Invest $5B in Galapagos Partnership

The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.

By Matthew Heller | July 15, 2019

Merck Agrees to Buy Peloton Therapeutics

Merck Agrees to Buy Peloton Therapeutics

The privately held cancer drugmaker had been set for a public offering Wednesday.

By Lauren Muskett | May 21, 2019

Pfizer Beats Estimates on Strength in Key Drugs

Financial Performance

Pfizer Beats Estimates on Strength in Key Drugs

Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.

By Matthew Heller | July 31, 2018

Shire Accepts Improved $62B Bid From Takeda

Shire Accepts Improved $62B Bid From Takeda

The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.

By Matthew Heller | May 8, 2018

Novartis to Buy AveXis in $8B Gene Therapy Bet

Novartis to Buy AveXis in $8B Gene Therapy Bet

The deal gives the Swiss drugmaker a neurological disease treatment that may have "a multi-billion dollar peak sales potential."

By Matthew Heller | April 9, 2018

Teva to Cut 14,000 Jobs in ‘Drastic’ Overhaul

Teva to Cut 14,000 Jobs in ‘Drastic’ Overhaul

The drugmaker says "there is no alternative" to its restructuring plan amid pricing pressure on its core generics business.

By Matthew Heller | December 14, 2017

Lilly Veteran Josh Smiley Promoted to CFO

Lilly Veteran Josh Smiley Promoted to CFO

Smiley takes over from Derica Rice amid a cost-cutting push aimed at freeing up cash for Lilly to invest in developing new drugs.

By Matthew Heller | October 2, 2017

Alexion to Cut 20% of Workforce, Move HQ

Alexion to Cut 20% of Workforce, Move HQ

The drugmaker is restructuring as it tries to rebuild its drug pipeline amid investigations of its sales practices.

By Matthew Heller | September 12, 2017

Eli Lilly to Trim 3,500 Jobs to Save $500 Million

Eli Lilly to Trim 3,500 Jobs to Save $500 Million

The drugmaker is seeking to become "a leaner, more nimble global organization" as it invests in a new generation of medicines.

By Matthew Heller | September 7, 2017